D-Index & Metrics Best Publications

Josef S. Smolen

Medical University of Vienna
Austria

Immunology

Austria

2022

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 167 Citations 133,705 1,351 World Ranking 315 National Ranking 2

Best Scientists D-index 167 Citations 133,814 1,377 World Ranking 629 National Ranking 2

Research.com Recognitions

Awards & Achievements

2023 - Research.com Best Scientist Award

2023 - Research.com Medicine in Austria Leader Award

2022 - Research.com Best Scientist Award

2022 - Research.com Medicine in Austria Leader Award

2022 - Research.com Immunology in Austria Leader Award

2020 - City of Vienna Prize for Science

2007 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology

Best Publications

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

P E Lipsky;D M van der Heijde;E W St Clair;D E Furst.
The New England Journal of Medicine (2000)

4628 Citations

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits.
Annals of the Rheumatic Diseases (2010)

4436 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)

4255 Citations

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

R Maini;E W St Clair;F Breedveld;D Furst.
The Lancet (1999)

3758 Citations

Treating rheumatoid arthritis to target: recommendations of an international task force

Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld.
Annals of the Rheumatic Diseases (2010)

2622 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados.
Annals of the Rheumatic Diseases (2010)

2305 Citations

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

M J Elliott;R N Maini;M Feldmann;J R Kalden.
The Lancet (1994)

2151 Citations

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen.
Arthritis & Rheumatism (1998)

2137 Citations

Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Claudio Vitali;Stefano Bombardieri;Haralampos M. Moutsopoulos;Genesio Balestrieri.
Arthritis & Rheumatism (1993)

1841 Citations

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang.
Arthritis & Rheumatism (2011)

1673 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Josef S. Smolen